sun pharmaceutical industries

Morgan Stanley bullish on these 2 pharma stocks which could give 32-47% return

Morgan Stanley also has overweight rating on Lupin with a target price at Rs 1,003, implying 47 percent potential upside from current levels as it believes the share price will rise in absolute terms over the next 30 days.

Sun Pharma arm acquires remaining 3.04% stake in PJSC Biosintez

The company's subsidiary -- Sun Pharma (Netherlands) BV -- already had 96.96 per cent stake in pharma firm PJSC Biosintez prior to the purchase of these shares, Sun Pharma said in a filing to the BSE.

Sun Pharma confirms SEBI forensic audit underway

Sun Pharma, however, did not provide any specific details on the reasons for the Securities and Exchange Board of India to order the forensic audit.

Sun Pharma climbs 5% after USFDA classifies Halol plant as 'No Action Indicated'

Halol is a crucial facility for Sun Pharma as it contributes around 15 percent of total US sales.

Hold Sun Pharmaceutical Industries; target of Rs 470: ICICI Direct

ICICI Direct recommended hold rating on Sun Pharmaceutical Industries with a target price of Rs 470 in its research report dated August 14, 2019.

Hold Sun Pharmaceutical Industries; target of Rs 500: Sharekhan

Sharekhan recommended Hold rating on Sun Pharmaceutical Industries with a target price of Rs 500 in its research report dated August 13, 2019.

Sun Pharma Q1 beats estimates, profit jumps 31% driven by India, US biz

Profit increased to Rs 1,387.5 crore in Q1, from Rs 1,057.3 crore in same period last year.

85 employees at Sun Pharma terminated as company shuts 2 units in Vadodara

Sun Pharma didn't disclose how many employees were impacted, but sources told Moneycontrol that 85 employees have been terminated.

Sun Pharma eyes 'low-to-mid teens' growth in revenues for FY20

The company is targeting key ailments like psoriasis to gradually ramp up its global specialty business, he said adding that Sun Pharma would continue to invest in branding and promotion of its various specialty products.

Sun Pharma gains 4% after Morgan Stanley's double upgrade, sees 24% upside

Morgan Stanley upgraded Sun Pharma to overweight and raised price target to Rs 505 from Rs 470 per share

Sun Pharma jumps 4% as CLSA sees 35% upside on strong India positioning

CLSA maintains buy rating on Sun Pharma with a price target at Rs 520 as stock remains attractive due to its strong India positioning

Sun Pharma gets 4 observations from USFDA for its Halol facility

The company will submit its response on the observations to the USFDA within 15 business days, Sun Pharma said.

Hold Sun Pharmaceutical Industries; target of Rs 460: ICICI Direct

ICICI Direct recommended hold rating on Sun Pharmaceutical Industries with a target price of Rs 460 in its research report dated May 29, 2019.

Hold Sun Pharmaceutical Industries; target of Rs 460: Sharekhan

Sharekhan recommended Hold rating on Sun Pharmaceutical Industries with a target price of Rs 460 in its research report dated May 28, 2019.

Sun Pharma Consolidated March 2019 Net Sales at Rs 7,163.92 crore, up 2.68% Y-o-Y

Sun Pharma Standalone March 2019 Net Sales at Rs 2,552.13 crore, up 11.78% Y-o-Y

Global brokerages stay positive on Sun Pharma, see 14-31% upside after Q4

Numbers, reported on May 28 after market hours, were below analyst estimates but adjusted earnings were in line with expectations

Sun Pharma gains on launch of ready-to-infuse Infugem in US

Sun Pharmaceutical Industries said Infugem (gemcitabine in sodium chloride injection), for intravenous use, is now commercially available in the US

Sun Pharma falls 1% on USFDA observation for Baska facility

The US Food and Drug Administration inspected company's Baska facility, in Gujarat, during January 28 to February 5.

Sun Pharma raises stake in Russia's PJSC Biosintez to 96.96%

After the completion of this purchase of shares, the total holding of wholly-owned subsidiary was increased from 85.10 per cent to 96.96 per cent in the Russian firm, it added.

Sun Pharma Consolidated December 2018 Net Sales at Rs 7,740.19 crore, up 16.34% Y-o-Y

Sun Pharma Standalone December 2018 Net Sales at Rs 2,261.26 crore, up 10.56% Y-o-Y

Sun Pharma Q3 preview: Analysts expect healthy growth in profit, revenue on US business

Emkay and Motilal Oswal see 17 percent year-on-year growth in bottomline while Prabhudas Lilladher expects profit to grow 137 percent and ICICI Securities expects 178 percent

SPARC rises 4% on milestone payment from parent co after commercialisation of Xelpros

Xelpros is used in the treatment for the reduction of elevated intraocular pressure (IOP, or pressure inside the eye) in patients with open-angle glaucoma or ocular hypertension.

2019 will be a good year for commodities, healthcare: Ajay Srivastava

Ajay Srivastava said he is not bullish on Sun Pharma because the structural story for the stock is not there and by and large it has been a big disappointment.